Home » Stocks » JNJ

Johnson & Johnson (JNJ)

Stock Price: $163.55 USD 1.82 (1.13%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $164.30 +0.75 (0.46%) Jan 22, 7:59 PM
Market Cap 432.91B
Revenue (ttm) 80.86B
Net Income (ttm) 16.99B
Shares Out 2.63B
EPS (ttm) 6.36
PE Ratio 25.72
Forward PE 17.73
Dividend $4.04
Dividend Yield 2.47%
Trading Day January 22
Last Price $163.55
Previous Close $161.73
Change ($) 1.82
Change (%) 1.13%
Day's Open 162.25
Day's Range 161.87 - 165.16
Day's Volume 8,137,018
52-Week Range 108.89 - 165.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 19 hours ago

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Other stocks mentioned: AZN, BAC, BNTX, MRNA, PFE
CNBC Television - 21 hours ago

Final Trades: Apple, IBM, Johnson & Johnson & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: IBM, AAPL, KLAC, VUZI
Zacks Investment Research - 23 hours ago

Regional Banks Post Mixed Earnings Results.

Other stocks mentioned: AAPL, ALLY, FB, FHB, HBAN, KSU, MSFT, NVS, SLB, TSLA
Zacks Investment Research - 1 day ago

J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.

New York Post - 1 day ago

Johnson & Johnson hopes to have enough COVID-19 vaccines for 100 million Americans by April as the feds ramp up nationwide inoculation efforts, a company official says.

New York Post - 1 day ago

Less may be more when it comes to rolling out a coronavirus vaccine. Johnson & Johnson's one-dose vaccine could have an edge over Pfizer and Moderna's shots– even though it's still several wee...

Benzinga - 1 day ago

Bloomberg reports that Johnson & Johnson (NYSE: JNJ) is on track to analyze data from its late-stage single-dose COVID-19 vaccine trial. Dr. Anthony Fauci said in his remarks at the White Hous...

The Motley Fool - 1 day ago

The lowest yield on this list is 2.5% and well above what the average S&P 500 stock pays today.

Other stocks mentioned: CAH, KMB
Seeking Alpha - 1 day ago

2020, for our investments, was a good year. We kept the cash from the Emera sale for emergency funds during the first lockdown when we weren't working.

Other stocks mentioned: AQN, ATGFF, BEPC, CVS, CWYUF, GD, IBM, LMT, MMM, MSFT, TRP, WCN
CNBC - 1 day ago

A J&J board member said “if the clinical trial works out,” the company could significantly increase the nation's Covid vaccine supply availability.

Seeking Alpha - 2 days ago

Starting 2021 by looking at the Long Ideas that performed poorly in 2020. Despite their underperformance, we remain bullish on these stocks, and they all remain open long ideas.

Other stocks mentioned: ALSN, KFY
The Dog of Wall Street - 2 days ago

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Other stocks mentioned: AXSM, NVAX
The Motley Fool - 2 days ago

This innovative drugmaker is expecting multiple growth catalysts in 2021.

The Motley Fool - 2 days ago

These stocks won't keep you up at night.

Other stocks mentioned: ABT, PFE
Seeking Alpha - 2 days ago

Healthcare aristocrats benefit from significant medical device contributions. By and large these healthcare aristocrats share favorable quant metrics on Seeking Alpha, albeit with significant ...

Other stocks mentioned: ABT, BDX, CAH, MDT
The Motley Fool - 2 days ago

Don't let an expensive share price stop you from buying the best.

Other stocks mentioned: GOOGL, MELI
Zacks Investment Research - 2 days ago

In the latest trading session, Johnson & Johnson (JNJ) closed at $162.38, marking a -0.25% move from the previous day.

InvestorPlace - 2 days ago

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...

Other stocks mentioned: AZN, BNTX, MRNA, NVAX, PFE
InvestorPlace - 3 days ago

If you have a long-term outlook for your portfolio, these beginner stocks to buy should make you very happy down the line. The post 9 Beginner Stocks for First-Time Investors appeared first on...

Other stocks mentioned: AAXN, ALB, COP, GLUU, HRB, KAMN, NEE, SCI
Seeking Alpha - 3 days ago

In December, we received $4,699.20 in dividend income. That is a 23.4% increase compared to last year. We received $3,500 from our retirement accounts this month alone. In total, our dividend ...

Other stocks mentioned: ADM, AEP, AFL, BAC, BP, CTVA, CVX, D, DD, DFS, DOW, ED, EMR, FE, IBM, ITOT, KHC, KR, MCD, MMM, NSC, PFE, SJM, SMG
InvestorPlace - 3 days ago

The Dow Jones Industrial Index is one of the cornerstone indexes of the U.S. markets. But it's more consumer-driven now.

Other stocks mentioned: AAPL, GS, MSFT, NKE, PG, WMT
Investopedia - 3 days ago

Nearby levels of support and recent closes beyond key resistance are creating lucrative risk/reward setups in the healthcare sector.

Other stocks mentioned: ABT, XLV
Forbes - 4 days ago

Starting 2021 by looking at the Long Ideas that performed poorly in 2020 that I remain bullish on.

Other stocks mentioned: ALSN, KFY
Forbes - 4 days ago

Johnson & Johnson is developing one of the most closely watched Covid-19 vaccines, considering that it is a single-dose shot that should be relatively easy to distribute. Here's a quick rundow...

The Motley Fool - 4 days ago

You can just sit back and watch the cash roll in with these two top stocks.

Other stocks mentioned: MMM
Zacks Investment Research - 4 days ago

J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.

The Motley Fool - 5 days ago

The possibility of a one-dose vaccine may give it an edge over rivals.

The Motley Fool - 6 days ago

Experts give their opinion of a conservative pick and a riskier one.

Other stocks mentioned: NVAX
Seeking Alpha - 6 days ago

Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AMGN, CAT, DIS, DOW, JPM, LPTH, MAA, MRK, NKE, NVR, VBIV
The Motley Fool - 1 week ago

Each has more to offer than just a COVID-19 vaccine.

Other stocks mentioned: NVAX, PFE
The Motley Fool - 1 week ago

Holding on to stocks for the long haul is a good way to build wealth -- as long as you've picked strong and growing enterprises. Here are three to consider.

Other stocks mentioned: MAR, MMM
CNBC Television - 1 week ago

New strains of virus discovered in the U.S., J&J vaccine generates immune response

Former FDA Commissioner Dr. Scott Gottlieb discusses news that two new Covid strains have been discovered in the U.S. by researchers at Ohio State University.

Zacks Investment Research - 1 week ago

Johnson & Johnson (JNJ) closed the most recent trading day at $160.65, moving +1.75% from the previous trading session.

CNBC Television - 1 week ago

J&J lab data is encouraging, need human trial data: Ex-CDC director

CNBC's "Closing Bell" team discusses Johnson & Johnson's latest data on its Covid vaccine and rollout in the U.S., with Dr. Tom Frieden, former CDC director.

The Motley Fool - 1 week ago

Those are some solid endorsements.

Other stocks mentioned: BMY, NVS, NVTA, RHHBY
Yahoo Finance - 1 week ago

Johnson & Johnson one dose vaccine sees immune response in early trials

Dr. Uche Blackstock, CEO of Advancing Health Equity and Yahoo News Medical Contributor weighs in on the Johnson & Johnson vaccine and the need to for the public to continue to follow measures ...

Seeking Alpha - 1 week ago

Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.

Other stocks mentioned: AWR, CLX, CVX, DTE, ENB, HD, MO, MRNA, PFE, T, V, XLE
Fox Business - 1 week ago

Johnson & Johnson one shot coronavirus vaccine is safe

Participants in the COVID-19 vaccine trials at Johnson & Johnson produced a positive immune response. Subscribe to Fox Business!

New York Post - 1 week ago

Johnson & Johnson's coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.

Market Watch - 1 week ago

Shares of Johnson & Johnson gained 1.7% in premarket trading on Thursday, the day after a study published in the New England Journal of Medicine showed that its COVID-19 vaccine candidate gene...

CNBC Television - 1 week ago

J&J reports positive phase 1/2 Covid vaccine trial results

CNBC's Meg Tirrell reports that Johnson & Johnson has seen positive results from its Covid vaccine trial. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Pete Najar...

CNBC - 1 week ago

The new clinical trial data shows a single shot of the vaccine "gives sustainable antibodies," Dr. Paul Stoffels, J&J chief scientific officer, told CNBC.

InvestorPlace - 1 week ago

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

Other stocks mentioned: ABBV, BMY, ELAN, JAZZ, MRNA, PFE
Investors Business Daily - 1 week ago

Johnson & Johnson said it's premature to discuss the details of its coronavirus vaccine supply after JNJ stock slipped Wednesday on a report it's two months behind schedule. The post J&J Stock...

The Motley Fool - 1 week ago

These stocks are as solid as they come.

Other stocks mentioned: ABBV, ABT
Reuters - 1 week ago

Johnson & Johnson is facing unexpected delays in the manufacturing of its coronavirus vaccine and may not be able to supply the doses it promised the federal government by spring, the New York...

Market Watch - 1 week ago

Federal officials have been told that Johnson & Johnson's vaccine production has fallen as much as two months behind the original production schedule and won't catch up until the end of April,...

Zacks Investment Research - 1 week ago

Johnson & Johnson (JNJ) closed at $158.13 in the latest trading session, marking a -0.78% move from the prior day.

The Motley Fool - 1 week ago

With solid valuations and good dividends, these businesses will get you through the next rainy day -- or year.

Other stocks mentioned: BMY, MPW
Seeking Alpha - 1 week ago

In this new series, I am hoping folks realize that the stocks I'm suggesting could provide an income for life, so you don't go broke before you kick the bucket. Obviously these should be a por...

About JNJ

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; ... [Read more...]

Industry
Drug Manufacturers-General
Founded
1886
CEO
Alex Gorsky
Employees
132,200
Stock Exchange
NYSE
Ticker Symbol
JNJ
Full Company Profile

Financial Performance

In 2019, JNJ's revenue was $82.06 billion, an increase of 0.59% compared to the previous year's $81.58 billion. Earnings were $15.12 billion, a decrease of -1.16%.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 168.18, which is an increase of 2.83% from the latest price.

Price Target
$168.18
(2.83% upside)
Analyst Consensus: Buy